Altshuler Shaham Ltd Has $1.83 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Altshuler Shaham Ltd raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6,619.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,502 shares of the pharmaceutical company’s stock after purchasing an additional 4,435 shares during the quarter. Vertex Pharmaceuticals makes up about 0.1% of Altshuler Shaham Ltd’s investment portfolio, making the stock its 24th largest position. Altshuler Shaham Ltd’s holdings in Vertex Pharmaceuticals were worth $1,832,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in VRTX. Venturi Wealth Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 1.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after purchasing an additional 24 shares in the last quarter. Nicholas Hoffman & Company LLC. grew its stake in Vertex Pharmaceuticals by 3.9% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after buying an additional 24 shares in the last quarter. Arthur M. Cohen & Associates LLC increased its holdings in Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after buying an additional 25 shares during the period. Baystate Wealth Management LLC increased its holdings in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the period. Finally, Arjuna Capital raised its position in shares of Vertex Pharmaceuticals by 0.7% in the 3rd quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after buying an additional 29 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, CAO Kristen Ambrose sold 1,374 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $577,409.76. Following the transaction, the chief accounting officer now owns 9,676 shares in the company, valued at approximately $4,066,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Vertex Pharmaceuticals news, CAO Kristen Ambrose sold 1,374 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $577,409.76. Following the sale, the chief accounting officer now owns 9,676 shares in the company, valued at $4,066,242.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now directly owns 27,644 shares in the company, valued at $11,596,934.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ:VRTX traded up $0.17 during midday trading on Thursday, hitting $418.99. 676,155 shares of the stock traded hands, compared to its average volume of 1,228,628. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $407.86 and its two-hundred day moving average is $400.88. The stock has a market capitalization of $108.29 billion, a PE ratio of 30.16, a P/E/G ratio of 1.89 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a one year low of $320.01 and a one year high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 earnings per share. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 6th. Wolfe Research assumed coverage on Vertex Pharmaceuticals in a research report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price objective for the company. Royal Bank of Canada lifted their target price on Vertex Pharmaceuticals from $417.00 to $424.00 and gave the company a “sector perform” rating in a research report on Tuesday. Piper Sandler increased their target price on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Oppenheimer restated an “outperform” rating and issued a $500.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $432.18.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.